WHWKWhitehawk Therapeutics Inc$ 4.1-

Whitehawk Therapeutics Inc

WHWK

NASDAQHealthcare

$ 4.1

Stock Score Analysis

20WEAK

HEALTH

Excellent

VALUATION

Overvalued

Key Metrics

Market Cap

283.18M

Dividend Yield (Est.)

0.00%

Revenue (TTM)

EPS (TTM)

$-1.68

PER (TTM)

-2.4x

PBR

2.44x

ROE (TTM)

-79.63%

ROA (TTM)

-91.02%

Equity Ratio

90.4%

1W Change

-6.83%

1M Change

-8.30%

6M Change

-16.59%

1Y Change

+119.89%

52W High

$5.50

52W Low

$1.80

About Whitehawk Therapeutics Inc

Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.

Read full overview

CEODavid J. Lennon

Founded2017

ExchangeNASDAQ

Analyst Ratings

Bullish: 80.0% (36 analysts: Very Bullish 12, Bullish 24)Bullish

80%

Neutral: 17.8% (8 analysts: Neutral 8)Neutral

18%

Bearish: 2.2% (1 analysts: Bearish 1, Very Bearish 0)Bearish

Median Target: $6.00 (45 analysts)Median Target$6.00

45 analysts

EPS Trend

(USD)

2020 Actual: -$0.21 (Est: -$2.11)

-2.11

-0.21

202020

2021 Actual: -$12.41 (Est: -$6.86)

-6.86

-12.4

212021

2022 Actual: -$2.69 (Est: -$2.88)

-2.88

-2.69

222022

2023 Actual: -$2.44 (Est: -$2.49)

-2.49

-2.44

232023

2024 Actual: -$2.36 (Est: -$2.04)

-2.04

-2.36

242024

2025 Actual: -$0.33 (Est: -$0.03)

-0.03

-0.33

252025

FY2026 Estimate: -$1.27

26 Est.2026 Est.

FY2027 Estimate: -$1.18

27 Est.2027 Est.

Analyst Est.

Actual

6Y Growth-57.1%

Market Sentiment & News

Latest First ▾

Press Release

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

2 days ago·PRNewsWire

Similar Stocks & Peers

Asset	Price	Div. Yield